A METHOD OF USING A SURROGATE FOR A THERAPEUTIC AGENT TO DETERMINE THE THERAPEUTIC DOSE FOR BONE MARROW ABLATION THERAPY

摘要

A method of using a surrogate, preferably <99m>Tc-MDP, for a therapeutic agent (for example, <166>Ho-EDTMP or preferably <166>Ho-DOTMP) to calculate the dosimetry for the therapeutic dose for bone marrow ablation therapy is disclosed. The advantages of this use of a surrogate in lieu of the therapeutic agent is lower cost, less exposure to high radiation levels, and length of the half-life, while maintaining the biodistribution in the total skeleton.